Immunovia expands multicenter clinical study for early detection of pancreatic cancer through collaboration with the renowned University of Pittsburgh
The collaboration with leading pancreas cancer centers in USA is a cornerstone of Immunovias reimbursement strategy and market introduction. The present expansion of PanFAM-1, the largest ever prospective multicenter study for early detection of pancreas cancer is another important step towards these goals. The study is designed to validate IMMrayTM PanCan-d, the first blood based test for early detection of pancreatic cancerImmunovia LUND, Sweden, and Pittsburgh, USA ― Immunovia AB today announced that University of Pittsburgh will be part of PanFAM-1, a multicenter prospective validation